Product Information
CARBIDOPA-LEVODOPA 25-250 TAB is a generic product labeled by Actavis Pharma, Inc., priced at $0.1104 per EA under NDC 00228254050. Its NADAC has been published 645 times since Nov 28, 2013.
FDA first approved this application on Sep 3, 1993. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 250 mg/1; mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00228254050
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
3/18/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA074260FDA Approved
9/3/1993
TE Code
AB
On Market Since
9/1/1993
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVODOPA 25-250 TAB has been published 645 times since Nov 28, 2013, and over the history we have for it it has declined 39.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1104 per EA |
|---|---|
| All-time high | $0.2020 (Apr 15, 2015) |
| All-time low | $0.0731 (Apr 17, 2024) |
| 52-week high | $0.1295 |
| 52-week low | $0.1104 |
| Median price | $0.1717 |
| Average price | $0.1637 |
| Largest weekly change | +71.8% (Jun 19, 2024) |
| Weeks tracked | 645 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
-13.4%
3Y
-22.0%
5Y
-37.3%
All
-39.4%
Last surveyed Apr 1, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Carbidopa and levodopa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVODOPA 25-250 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVODOPA 25-250 TAB, manufactured by Actavis Pharma, Inc., is $0.1104 per EA (NDC 00228254050), effective Apr 1, 2026.
How has the price of CARBIDOPA-LEVODOPA 25-250 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVODOPA 25-250 TAB has declined 39.4%. It has been tracked across 645 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVODOPA 25-250 TAB?
Since Nov 28, 2013, the NADAC for CARBIDOPA-LEVODOPA 25-250 TAB has ranged from a low of $0.0731 (Apr 17, 2024) to a high of $0.2020 (Apr 15, 2015), with a median of $0.1717 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVODOPA 25-250 TAB?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CARBIDOPA-LEVODOPA 25-250 TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures CARBIDOPA-LEVODOPA 25-250 TAB?
CARBIDOPA-LEVODOPA 25-250 TAB (NDC 00228254050) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.